A Phase 3 interventional study of maraviroc in HIV Infections, sponsored by ViiV Healthcare. Completed at 361 sites in 26 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-06-29.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing maraviroc in HIV Infections — none open to participants now, none under way, none of them phase 3. Maraviroc · HIV Infections.
Among the 44 studies testing maraviroc in HIV Infections, this one has the largest enrollment, is one of 5 that started in 2007, is one of 7 in phase 3, and was the 2nd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 44 studies testing maraviroc in HIV Infections is open now. The open studies under HIV Infections, anywhere →
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 9 · Phase 4 15
First in 2002; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,047 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 36 across the 44 interventional studies. Of the 42 that completed or were terminated, 23 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 4th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2007, is one of 65 in phase 3, and was the 111th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing maraviroc in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: maraviroc
The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)
AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.
Time frame: Baseline up to Week 144
Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline Abnormalities
Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3, Severe =events that interrupted participants usual daily activity and traditionally required systemic drug therapy or other treatment.
Time frame: Baseline up to Week 144
Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline Abnormalities
Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 4, Very Severe = events which were unacceptable and intolerable or were irreversible or caused the participant to be in imminent danger of death.
Time frame: Baseline up to Week 144
Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Illnesses
Treatment-emergent AIDS-defining opportunistic illnesses based on investigator classification guided by a predefined list of clinical Category C adverse events per Center for Disease Control (CDC) HIV Classification System. Includes events occurring up to 30 days after last dose of study drug.
Time frame: Baseline up to Week 144
Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral Load
Time frame: Baseline up to Week 144
Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell Counts
Time frame: Baseline up to Week 144
Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on Therapy
Time frame: Baseline up to Week 144
Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by Gender
Treatment-emergent AEs by gender that occurred up to 30 days after the last dose of study medication.
Time frame: Baseline up to Week 144
Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Race
Treatment-emergent AEs by race that occurred up to 30 days after the last dose of study medication.
Time frame: Baseline up to Week 144
Percentage of Participants With Treatment-emergent Adverse Events (AEs) by Age
Treatment-emergent AEs by age that occurred up to 30 days after the last dose of study medication.
Time frame: Baseline up to Week 144
Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology Status
Treatment emergent AEs by hepatis B and hepatitis C serology status that occurred up to 30 days post last dose.
Time frame: Baseline up to Week 144
Percentage of Participants With ≥0.5 log10 Reduction From Baseline in Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV 1 RNA)
Defined as HIV-1 RNA levels \< 400 Copies/mL or at least 0.5 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.
Time frame: Baseline up to Week 144
Percentage of Participants With ≥1.0 log10 Reduction From Baseline in HIV 1 RNA
Defined as HIV-1 RNA levels \< 400 copies/mL or at least 1.0 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.
Time frame: Baseline up to Week 144
Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <400 Copies/mL
Limit of quantification defined as \<400 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.
Time frame: Baseline up to Week 144
Percentage of Participants With HIV-1 RNA Levels Below the Limit of Quantification: <50 Copies/mL
Limit of quantification defined as \<50 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.
Time frame: Baseline up to Week 144
Change From Baseline in CD4 Cell Count
Change from baseline in cluster of differentiation 4 helper T cells (CD4) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.
Time frame: Baseline up to Week 144
Change From Baseline in CD4 Cell Count Percent
Change from baseline in CD4 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.
Time frame: Baseline up to Week 144
Change From Baseline in CD8 Cell Count
Change from baseline in cluster of differentiation 8 suppressor T cells (CD8) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.
Time frame: Baseline up to Week 144
Change From Baseline in CD8 Cell Count Percent
Change from baseline in CD8 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.
Time frame: Baseline up to Week 144
Median Time to Virologic Failure
Computed as time from the first dose of study medication to the loss of virologic response. Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥ 0.5 log10 copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.
Time frame: Day 1 up to Week 144
Percentage of Participants With Changes in HIV-1 RNA Level in Participants Meeting the Definition of Virologic Failure
Reasons for virologic failure: A) failure to achieve a reduction in HIV-1 RNA\>=0.5 log10 copies/ml from baseline (BL) by second viral load determination (unless below level of quantification \[LOQ\]); B) \>=0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from BL \>0.5 log10 copies/ml ; C) HIV-1 RNA \>1000 copies/ml after having achieved an HIV-1 RNA below LOQ.
Time frame: Baseline up to Week 144
Percentage of Participants With Change in Chemokine Co-receptor Tropism From Screening to Time of Virologic Failure
Tropism status (CCR5 \[R5\], CXCR4 \[X4\], Dual Mixed \[DM\], or Non-reportable \[NR\]) at Screening (Scr) and time of virologic failure (V fail). Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥0.5 log10 copies/mL by second viral load determination (unless viral load was below lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.
Time frame: Screening up to Week 144
Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau
Resistance to maravroc in viruses from participants failing therapy with R5 virus was investigated using the in vitro phenotypic (drug susceptibility) assay. The number of participants who failed with R5 virus were assessed successfully for maraviroc susceptibility at Baseline and Last on--treatment (Week 144). Samples were analyzed for change from Baseline to time of virologic failure in IC 50 and presence of plateau. A maximal percent inhibition (MPI) \<95% established as a plateau in inhibition at high concentrations of maraviroc was used to identify viruses which had reduced phenotypic susceptibility to maraviroc.
Time frame: Baseline up to Week 144
Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120)
Virus from participants who experienced virologic failure was analyzed for resistance to maraviroc. Resistance testing was performed on archived samples of participants which were available pre--treatment at time of virologic failure. For participants who met definition of virologic failure during the trial, the sequencing of the V3 loop of HIV--1 viral envelope gp 120 was evaluated to identify any amino acid changes concomitant with decreased susceptibility to maraviroc.
Time frame: Baseline up to Week 144
| Milestone | Maraviroc |
|---|---|
| Started | 1047 |
| Treated | 1032 |
| Safety analysis set | 1032 |
| Completed | 916 |
| Not completed | 131 |
| Withdrew: Death | 14 |
| Withdrew: Adverse event | 23 |
| Withdrew: Insufficient clinical response | 22 |
| Withdrew: Lost to follow-up | 15 |
| Withdrew: Other | 23 |
| Withdrew: Withdrawal by subject | 18 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Enrolled not treated | 15 |
AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.
| percentage of participants | Maraviroc |
|---|---|
| Grade 3 AE: all causality | 13.2 |
| Grade 3 AE: treatment related | 2.4 |
| Grade 4 AE: all causality | 6.3 |
| Grade 4 AE: treatment related | 1.6 |
Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3, Severe =events that interrupted participants usual daily activity and traditionally required systemic drug therapy or other treatment.
| percentage of participants | Maraviroc |
|---|---|
| Alanine aminotransferase (ALT) (n=1013) | 2.17 |
| Aspartate aminotransferase (AST) (n=1013) | 2.07 |
| Absolute Neutrophil Count (n=1004) | 0.70 |
| Alkaline Phosphatase (n=1014) | 0.39 |
| Creatinine (n=1014) | 0.49 |
| Gamma-glutamyl transpeptidase (GGT) (n=1014) | 4.73 |
| Hemoglobin (n=1005) | 0.20 |
| Hyperbilirubinemia (n=1013) | 1.28 |
| Hyperuricemia (n=1014) | 0.69 |
| Hypophosphatemia (n=1014) | 0.20 |
| Lipase (n=409) | 4.40 |
| Platelets (n=997) | 1.50 |
| Potassium (hyperkalemia) (n=1014) | 0.10 |
| Serum Amylase (n=1014) | 4.83 |
| Sodium (hypernatremia) (n=1014) | 0.10 |
| Triglycerides (n=1014) | 4.73 |
Laboratory abnormalities as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 4, Very Severe = events which were unacceptable and intolerable or were irreversible or caused the participant to be in imminent danger of death.
| percentage of participants | Maraviroc |
|---|---|
| ALT (n=1013) | 0.79 |
| AST (n=1013) | 0.39 |
| Absolute Neutrophil Count (n=1004) | 0.20 |
| Alkaline Phosphatase (n=1014) | 0.00 |
| Creatinine (n=1014) | 0.10 |
| GGT (n=1014) | 1.48 |
| Hemoglobin (n=1005) | 0.10 |
| Hyperbilirubinemia (n=1013) | 0.30 |
| Hyperuricemia (n=1014) | 0.10 |
| Hypophosphatemia (n=1014) | 0.00 |
| Lipase (n=409) | 1.22 |
| Platelets (n=997) | 0.30 |
| Potassium (hyperkalemia) (n=1014) | 0.20 |
| Serum Amylase (n=1014) | 0.30 |
| Sodium (hypernatremia) (n=1014) | 0.20 |
| Triglycerides (n=1014) | 1.97 |
Treatment-emergent AIDS-defining opportunistic illnesses based on investigator classification guided by a predefined list of clinical Category C adverse events per Center for Disease Control (CDC) HIV Classification System. Includes events occurring up to 30 days after last dose of study drug.
| percentage of participants | Maraviroc |
|---|---|
| AIDS encephalopathy | 0.1 |
| Bone tuberculosis | 0.1 |
| Cytomegalovirus infection | 0.2 |
| Extrapulmonary tuberculosis | 0.1 |
| Meningitis cryptococcal | 0.1 |
| Meningitis tuberculous | 0.1 |
| Mycobacterium avium complex infection | 0.1 |
| Mycobacterium kansasii infection | 0.1 |
| Oesophageal candidiasis | 0.6 |
| Pancreatitis bacterial | 0.1 |
| Pneumocystis jiroveci pneumonia | 0.1 |
| Progressive multifocal leukoencephalopathy | 0.1 |
| Pulmonary tuberculosis | 0.5 |
| Toxoplasmosis | 0.1 |
| B-cell lymphoma | 0.1 |
| Hodgkin's disease | 0.1 |
| Kaposi's sarcoma | 0.2 |
| Encephalopathy | 0.1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Treatment-emergent AEs by gender that occurred up to 30 days after the last dose of study medication.
| percentage of participants | Maraviroc |
|---|---|
| Male (n=827) | 69.6 |
| Female (n=205) | 73.7 |
Treatment-emergent AEs by race that occurred up to 30 days after the last dose of study medication.
| percentage of participants | Maraviroc |
|---|---|
| White (n=817) | 68.5 |
| Black (n=106) | 67.9 |
| Asian (n=54) | 88.9 |
| Other Unspecified (n=55) | 85.5 |
Treatment-emergent AEs by age that occurred up to 30 days after the last dose of study medication.
| percentage of participants | Maraviroc |
|---|---|
| <18 years (n=1) | 100.0 |
| 18 to 44 years (n=515) | 71.7 |
| 45 to 64 years (n=493) | 68.6 |
| >=65 years (n=23) | 82.6 |
Treatment emergent AEs by hepatis B and hepatitis C serology status that occurred up to 30 days post last dose.
| percentage of participants | Maraviroc |
|---|---|
| HBV: negative (n=897) | 71.3 |
| HBV: positive (n=60) | 65.0 |
| HBV: missing: (n=75) | 64.0 |
| HCV: negative (n=794) | 72.7 |
| HCV: positive (n=158) | 62.7 |
| HCV: missing (n=80) | 63.8 |
Defined as HIV-1 RNA levels \< 400 Copies/mL or at least 0.5 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.
| percentage of participants | Maraviroc |
|---|---|
| Day 2-7 (n=26) | 46.2 |
| Week 2 (n=226) | 93.8 |
| Week 4 (n=773) | 93 |
| Week 8 (n=761) | 93.2 |
| Week 12 (n=756) | 94 |
| Week 16 (n=155) | 87.7 |
| Week 20 (n=131) | 93.1 |
| Week 24 (n=557) | 91.9 |
| Week 32 (n=202) | 93.1 |
| Week 40 (n=227) | 91.2 |
| Week 48 (n=228) | 89 |
| Week 60 (n=160) | 90 |
| Week 72 (n=125) | 88 |
| Week 84 (n=79) | 84.8 |
| Week 96 (n=48) | 91.7 |
| Week 108 (n=18) | 100 |
| Week 120 (n=9) | 100 |
| Week 132 (n=4) | 100 |
| Week 144 (n=1) | 100 |
Defined as HIV-1 RNA levels \< 400 copies/mL or at least 1.0 Log 10-decrease from baseline in HIV-1 RNA levels. Baseline value calculated as average of the screening and baseline values if both values were within 1 log10 difference.
| percentage of participants | Maraviroc |
|---|---|
| Day 2-7 (n=26) | 30.8 |
| Week 2 (n=226) | 90.3 |
| Week 4 (n=773) | 90.2 |
| Week 8 (n=761) | 91.2 |
| Week 12 (n=756) | 91.3 |
| Week 16 (n=155) | 82.6 |
| Week 20 (n=131) | 89.3 |
| Week 24 (n=557) | 89 |
| Week 32 (n=202) | 90.1 |
| Week 40 (n=227) | 87.7 |
| Week 48 (n=228) | 86.4 |
| Week 60 (n=160) | 85.6 |
| Week 72 (n=125) | 83.2 |
| Week 84 (n=79) | 79.7 |
| Week 96 (n=48) | 85.4 |
| Week 108 (n=18) | 100 |
| Week 120 (n=9) | 100 |
| Week 132 (n=4) | 100 |
| Week 144 (n=1) | 100 |
Limit of quantification defined as \<400 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.
| percentage of participants | Maraviroc |
|---|---|
| Baseline (n=979) | 6.7 |
| Day 2-7 (n=26) | 3.8 |
| Week 2 (n=226) | 58.8 |
| Week 4 (n=773) | 72.7 |
| Week 8 (n=761) | 78.8 |
| Week 12 (n=756) | 82.5 |
| Week 16 (n=155) | 75.5 |
| Week 20 (n=131) | 83.2 |
| Week 24 (n=557) | 84.4 |
| Week 32 (n=202) | 83.7 |
| Week 40 (n=227) | 81.1 |
| Week 48 (n=228) | 80.7 |
| Week 60 (n=160) | 78.1 |
| Week 72 (n=125) | 72.8 |
| Week 84 (n=79) | 74.7 |
| Week 96 (n=48) | 75.0 |
| Week 108 (n=18) | 88.9 |
| Week 120 (n=9) | 77.8 |
| Week 132 (n=4) | 100 |
| Week 144 (n=1) | 100 |
Limit of quantification defined as \<50 copies/mL. Baseline value calculated as average of the screening and baseline values if both values were within 1 log 10 difference.
| percentage of participants | Maraviroc |
|---|---|
| Baseline (n=979) | 1.7 |
| Day 2-7 (n=26) | 0.0 |
| Week 2 (n=226) | 19.9 |
| Week 4 (n=773) | 30.1 |
| Week 8 (n=761) | 43.1 |
| Week 12 (n=756) | 45.8 |
| Week 16 (n=155) | 37.4 |
| Week 20 (n=131) | 42.7 |
| Week 24 (n=557) | 55.8 |
| Week 32 (n=202) | 57.4 |
| Week 40 (n=227) | 54.6 |
| Week 48 (n=228) | 54.8 |
| Week 60 (n=160) | 51.9 |
| Week 72 (n=125) | 49.6 |
| Week 84 (n=79) | 55.7 |
| Week 96 (n=48) | 54.2 |
| Week 108 (n=18) | 77.8 |
| Week 120 (n=9) | 44.4 |
| Week 132 (n=4) | 75.0 |
| Week 144 (n=1) | 100 |
Change from baseline in cluster of differentiation 4 helper T cells (CD4) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.
| cells/uL | Maraviroc |
|---|---|
| Day 2-7 (n=6) | 28.5 ± 76.18 |
| Week 2 (n=213) | 49.7 ± 93.15 |
| Week 4 (n=762) | 68.9 ± 124.31 |
| Week 8 (n=739) | 94.5 ± 122.94 |
| Week 12 (n=738) | 95.7 ± 124.42 |
| Week 16 (n=149) | 85.9 ± 124.37 |
| Week 20 (n=130) | 106.6 ± 112.26 |
| Week 24 (n=552) | 127.8 ± 139.42 |
| Week 32 (n=197) | 124.1 ± 150.44 |
| Week 40 (n=232) | 129.2 ± 144.31 |
| Week 48 (n=222) | 140.5 ± 154.46 |
| Week 60 (n=161) | 134.0 ± 151.52 |
| Week 72 (n=124) | 147.0 ± 160.92 |
| Week 84 (n=72) | 141.1 ± 147.55 |
| Week 96 (n=50) | 160.3 ± 160.78 |
| Week 108 (n=19) | 242.9 ± 167.06 |
| Week 120 (n=8) | 117.9 ± 203.49 |
| Week 132 (n=4) | 179.0 ± 109.94 |
| Week 144 (n=1) | 93.0 ± NA |
Change from baseline in CD4 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.
| percentage of lymphocytes | Maraviroc |
|---|---|
| Days 2-7 (n=6) | -1.3 ± 1.56 |
| Week 2 (n=206) | 1.8 ± 3.79 |
| Week 4 (n=733) | 1.6 ± 4.84 |
| Week 8 (n=722) | 1.4 ± 6.12 |
| Week 12 (n=708) | 1.6 ± 5.45 |
| Week 16 (n=141) | 1.9 ± 4.63 |
| Week 20 (n=125) | 2.2 ± 6.17 |
| Week 24 (n=531) | 2.8 ± 4.55 |
| Week 32 (n=191) | 3.2 ± 5.38 |
| Week 40 (n=218) | 3.7 ± 4.97 |
| Week 48 (n=210) | 3.5 ± 5.87 |
| Week 60 (n=148) | 4.5 ± 6.10 |
| Week 72 (n=116) | 5.0 ± 6.33 |
| Week 84 (n=64) | 5.7 ± 6.73 |
| Week 96 (n=41) | 3.9 ± 6.36 |
| Week 108 (n=19) | 6.3 ± 6.86 |
| Week 120 (n=7) | 5.7 ± 9.07 |
| Week 132 (n=4) | 8.5 ± 8.35 |
| Week 144 (n=1) | 1.0 ± 0.0 |
Change from baseline in cluster of differentiation 8 suppressor T cells (CD8) cell count. If baseline value was not available, it was taken from immediate preceding non-missing value.
| cells/uL | Maraviroc |
|---|---|
| Day 2-7 (n=6) | 268.5 ± 262.50 |
| Week 2 (n=201) | 78.2 ± 343.85 |
| Week 4 (n=701) | 205.6 ± 509.70 |
| Week 8 (n=692) | 345.6 ± 599.98 |
| Week 12 (n=696) | 309.4 ± 578.91 |
| Week 16 (n=129) | 259.6 ± 430.78 |
| Week 20 (n=119) | 325.2 ± 621.46 |
| Week 24 (n=523) | 251.3 ± 498.85 |
| Week 32 (n=185) | 185.2 ± 484.74 |
| Week 40 (n=222) | 160.9 ± 471.99 |
| Week 48 (n=214) | 153.2 ± 464.73 |
| Week 60 (n=157) | 76.9 ± 467.64 |
| Week 72 (n=120) | 68.7 ± 502.73 |
| Week 84 (n=70) | -11.6 ± 548.85 |
| Week 96 (n=45) | 56.6 ± 403.10 |
| Week 108 (n=19) | 147.5 ± 600.55 |
| Week 120 (n=8) | -135.1 ± 517.02 |
| Week 132 (n=4) | -363.3 ± 882.30 |
| Week 144 (n=1) | 642.0 ± 0.0 |
Change from baseline in CD8 cell count percent . If baseline value was not available, it was taken from immediate preceding non-missing value.
| percentage of lymphocytes | Maraviroc |
|---|---|
| Day 2-7 (n=6) | 3.0 ± 3.42 |
| Week 2 (n=197) | -1.5 ± 7.68 |
| Week 4 (n=689) | -0.3 ± 8.08 |
| Week 8 (n=683) | 0.4 ± 9.62 |
| Week 12 (n=675) | -0.9 ± 9.95 |
| Week 16 (n=125) | 0.7 ± 8.66 |
| Week 20 (n=115) | -0.7 ± 10.08 |
| Week 24 (n=510) | -3.2 ± 8.92 |
| Week 32 (n=184) | -4.0 ± 9.09 |
| Week 40 (n=215) | -4.5 ± 8.90 |
| Week 48 (n=202) | -5.1 ± 10.63 |
| Week 60 (n=146) | -5.0 ± 11.90 |
| Week 72 (n=113) | -6.2 ± 9.87 |
| Week 84 (n=64) | -8.2 ± 15.52 |
| Week 96 (n=40) | -9.5 ± 10.18 |
| Week 108 (n=19) | -14.5 ± 9.99 |
| Week 120 (n=6) | -14.5 ± 13.41 |
| Week 132 (n=4) | -16.8 ± 12.89 |
| Week 144 (n=1) | -2.0 ± 0.0 |
Computed as time from the first dose of study medication to the loss of virologic response. Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥ 0.5 log10 copies /mL by the second viral load determination (unless viral load was below the lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving a HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.
| days | Maraviroc |
|---|---|
| Median Time to Virologic Failure | 86.5 (58.0 to 169.0) |
Reasons for virologic failure: A) failure to achieve a reduction in HIV-1 RNA\>=0.5 log10 copies/ml from baseline (BL) by second viral load determination (unless below level of quantification \[LOQ\]); B) \>=0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from BL \>0.5 log10 copies/ml ; C) HIV-1 RNA \>1000 copies/ml after having achieved an HIV-1 RNA below LOQ.
| percentage of participants | Maraviroc |
|---|---|
| Reduction in HIV-1 RNA<0.5 log10 copies/ml | 43.75 |
| >=0.5 log10 increase from nadir in HIV-1 RNA | 31.77 |
| HIV-1 RNA >1000 copies/ml | 18.75 |
| Reduction <0.5 log10 + HIV-1 RNA >1000 copies/ml | 3.13 |
| >=0.5 log10 increase from nadir + HIV-1 RNA >1000 | 2.60 |
Tropism status (CCR5 \[R5\], CXCR4 \[X4\], Dual Mixed \[DM\], or Non-reportable \[NR\]) at Screening (Scr) and time of virologic failure (V fail). Virologic failure defined as: failure to achieve a reduction from baseline (BL) in HIV 1 RNA ≥0.5 log10 copies/mL by second viral load determination (unless viral load was below lower limit level of quantification \[LLOQ\]); or a ≥ 0.5 log10 increase from nadir in HIV 1 RNA after achieving HIV 1 RNA reduction from BL \>0.5 log10 copies/mL; or a HIV 1 RNA level of \>1000 copies/mL after having achieved a HIV 1 RNA level below LLOQ.
| percentage of participants | Maraviroc |
|---|---|
| Scr: Missing; V fail: R5 | 5.73 |
| Scr: Missing; V fail: X4 | 0.52 |
| Scr: Missing; V fail: DM | 1.04 |
| Scr: Missing; V fail: NR | 7.29 |
| Scr: Missing; V fail: Missing | 1.56 |
| Scr: NR; V fail: R5 | 0.52 |
| Scr: R5; V fail: R5 | 31.25 |
| Scr: R5; V fail: X4 | 4.17 |
| Scr: R5; V fail: DM | 18.75 |
| Scr: R5; V fail: NR | 22.92 |
| Scr: R5; V fail: Missing | 6.25 |
Resistance to maravroc in viruses from participants failing therapy with R5 virus was investigated using the in vitro phenotypic (drug susceptibility) assay. The number of participants who failed with R5 virus were assessed successfully for maraviroc susceptibility at Baseline and Last on--treatment (Week 144). Samples were analyzed for change from Baseline to time of virologic failure in IC 50 and presence of plateau. A maximal percent inhibition (MPI) \<95% established as a plateau in inhibition at high concentrations of maraviroc was used to identify viruses which had reduced phenotypic susceptibility to maraviroc.
| participants | Maraviroc |
|---|---|
| Number of Participants With Reduced Maraviroc Susceptibility as Defined by Change From Baseline to Time of Virologic Failure in Inhibitory Concentration of 50% (IC 50) and Presence of Plateau | 14 |
Virus from participants who experienced virologic failure was analyzed for resistance to maraviroc. Resistance testing was performed on archived samples of participants which were available pre--treatment at time of virologic failure. For participants who met definition of virologic failure during the trial, the sequencing of the V3 loop of HIV--1 viral envelope gp 120 was evaluated to identify any amino acid changes concomitant with decreased susceptibility to maraviroc.
| participants | Maraviroc |
|---|---|
| Number of Participants With Emergence of Resistance to Maraviroc as Defined by Genotypic Changes in the V3 Loop of Glycoprotein 120 (gp 120) | NA |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc | — | 139/1,032 (13.5%) | 700/1,032 (67.8%) |
| Event | Maraviroc |
|---|---|
| PneumoniaInfections and infestations | 11/1032 |
| PyrexiaGeneral disorders | 10/1032 |
| DiarrhoeaGastrointestinal disorders | 7/1032 |
| Chest painGeneral disorders | 7/1032 |
| AnaemiaBlood and lymphatic system disorders | 5/1032 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/1032 |
| Cytolytic hepatitisHepatobiliary disorders | 4/1032 |
| Urinary tract infectionInfections and infestations | 4/1032 |
| Renal failure acuteRenal and urinary disorders | 4/1032 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/1032 |
| Event | Maraviroc |
|---|---|
| DiarrhoeaGastrointestinal disorders | 94/1032 |
| BronchitisInfections and infestations | 67/1032 |
| HeadacheNervous system disorders | 66/1032 |
| NauseaGastrointestinal disorders | 60/1032 |
| PyrexiaGeneral disorders | 50/1032 |
| CoughRespiratory, thoracic and mediastinal disorders | 47/1032 |
| Back painMusculoskeletal and connective tissue disorders | 45/1032 |
| RashSkin and subcutaneous tissue disorders | 44/1032 |
| NasopharyngitisInfections and infestations | 41/1032 |
| Upper respiratory tract infectionInfections and infestations | 41/1032 |
| Age, Continuous(years) | Maraviroc |
|---|---|
| Mean | 45.6 ± 8.6 |
| Sex: Female, Male(Participants) | Maraviroc |
|---|---|
| Female | 205 |
| Male | 827 |
| Baseline Viral Load: Absolute Value(copies/mL) | Maraviroc |
|---|---|
| Overall: Absolute (N=979) | 117846.1 ± 321426.5 |
| < 100,000: Absolute (N=729) | 22395.9 ± 25974.4 |
| >= 100,000: Absolute (N=250) | 396179.0 ± 547142.6 |
| Baseline Viral Load: Absolute Value(copies/mL) | Maraviroc |
|---|---|
| Overall: Absolute (N=979) | 25109.5 (39.0 to 5728492.0) |
| < 100,000: Absolute (N=729) | 11028.5 (39.0 to 99643.0) |
| >= 100,000: Absolute (N=250) | 234750.0 (100000.0 to 5728492.0) |
| Baseline Viral Load: Log Scale(log10 copies/mL) | Maraviroc |
|---|---|
| Overall: Log Scale (N=979) | 4.259 ± 1.0182 |
| < 100,000: Log Scale (N=729) | 3.859 ± 0.8517 |
| >= 100,000: Log Scale (N=250) | 5.423 ± 0.3496 |
| Baseline Viral Load: : Log Scale(log10 copies/mL) | Maraviroc |
|---|---|
| Overall: Log Scale (N=979) | 4.400 (1.591 to 6.758) |
| < 100,000: Log Scale (N=729) | 4.043 (1.591 to 4.998) |
| >= 100,000: Log Scale (N=250) | 5.371 (5.000 to 6.758) |
Showing the first 100 of 361 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc